KRAS mutation allele frequency threshold alters prognosis in right‐sided resected pancreatic cancer

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

(2021) Cara Kenney et al.   INVESTIGATIONAL NEW DRUGS

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

(2021) Alice Indini et al.   Pharmaceutics

Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors

(2021) Jun Ushio et al.   Diagnostics

Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival

(2021) Giulio Belfiori et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting KRAS in pancreatic cancer: new drugs on the horizon

(2021) Sahar F. Bannoura et al.   CANCER AND METASTASIS REVIEWS

Homologous recombination repair gene mutations in Chinese pancreatic ductal adenocarcinoma patients.

(2021) Nengwen Ke et al.   JOURNAL OF CLINICAL ONCOLOGY

Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing

(2021) Yan Helen Yan et al.   Scientific Reports

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples

(2020) Joanne M. Mankor et al.   BRITISH JOURNAL OF CANCER

The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia

(2020) David C. Linch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

(2020) Michael J Pishvaian et al.   LANCET ONCOLOGY

Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer

(2020) Fumiaki Watanabe et al.   PLoS One

Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands

(2020) Lois A. Daamen et al.   ANNALS OF SURGERY

Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer

(2020) Kanchan Singh et al.   LABORATORY INVESTIGATION

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing

(2020) Matilda Holm et al.   PLoS One

Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis

(2019) Divya Thomas et al.   Molecular Cancer

Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?

(2019) Tamara M.H. Gall et al.   Oncotarget

Analysis of heritability and genetic architecture of Pancreatic Cancer: A PanC4 Study

(2019) Fei Chen et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Next-Generation Sequencing in Pancreatic Cancer

(2019) Gong-Qing Shen et al.   PANCREAS

The Use of Genetically Engineered Mouse Models for Studying the Function of Mutated Driver Genes in Pancreatic Cancer

(2019) Weng et al.   Journal of Clinical Medicine

Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia

(2019) Koji Sasaki et al.   CANCER

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer

(2019) Sumitra Mohan et al.   Scientific Reports

Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma

(2018) Vincent P. Groot et al.   ANNALS OF SURGICAL ONCOLOGY

Frequency distribution of HLA alleles and haplotypes in Uyghur women with advanced squamous cell cervical cancer and relation to HPV status and clinical outcome

(2018) Mayinuer Alifu et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy

(2018) Irene Ferrer et al.   LUNG CANCER

Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection

(2018) Lianhua Dong et al.   Scientific Reports

Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma

(2018) Jie Ma et al.   BMC CANCER

Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma

(2017) Koji Shindo et al.   JOURNAL OF CLINICAL ONCOLOGY

Current and future therapies for advanced pancreatic cancer

(2017) Rohan Gupta et al.   JOURNAL OF SURGICAL ONCOLOGY

Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993–2013

(2017) Talia Golan et al.   Journal of the National Comprehensive Cancer Network

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

(2017) Hyun-Tae Shin et al.   Nature Communications

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

(2017) Andrew M. Waters et al.   Cold Spring Harbor Perspectives in Medicine

Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals

(2017) Ligang Xia et al.   Scientific Reports

Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer

(2016) Irina Heid et al.   CLINICAL CANCER RESEARCH

Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?

(2016) Alexander A. Parikh et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

(2016) Julien Taieb et al.   JNCI-Journal of the National Cancer Institute

KRAS-related proteins in pancreatic cancer

(2016) Karen M. Mann et al.   PHARMACOLOGY & THERAPEUTICS

Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

(2016) Julien Taieb et al.   JNCI-Journal of the National Cancer Institute

Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients

(2015) C. Hu et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Allelic Ratio of KRAS Mutations in Pancreatic Cancer

(2015) J. K. Lennerz et al.   ONCOLOGIST

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

(2015) Agnieszka K. Witkiewicz et al.   Nature Communications

Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing

(2014) Ming-Tseh Lin et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation

(2014) A. Ono et al.   ANNALS OF ONCOLOGY

Molecular pathology of pancreatic cancer

(2014) Yuriko Saiki et al.   PATHOLOGY INTERNATIONAL

Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma

(2012) Dong Tang et al.   INTERNATIONAL JOURNAL OF CANCER

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

(2012) Andrew V. Biankin et al.   NATURE

Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas

(2012) Nicolai Aagaard Schultz et al.   PANCREAS

A KrasG12D-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis

(2011) C A Whipple et al.   ONCOGENE

Genome-wide Significant Associations for Variants With Minor Allele Frequency of 5% or Less—An Overview: A HuGE Review

(2010) Orestis A. Panagiotou et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma

(2010) Jennifer P. Morton et al.   GASTROENTEROLOGY